Recent advances in enzymeless-based electrochemical sensors to diagnose neurodegenerative diseases

Song, Zeyu; Zhou, Ying; Han, Xiao; Qin, Jieling; Tang, Xiaoying

doi:10.1039/d0tb02745f

Cited by 29 publications

(24 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can also be utilized in vivo, allowing for the continuous monitoring of relevant biomarkers in the brain. 27 The analyte recognition elements like antibodies, receptors, enzymes, etc., have also been modified at the nanoscale. The development of nano-receptors based on self-organization and structural flexibility using nanoparticles wrapped in an organic ligand shell is intriguing and promising for biosensors.…”

Section: Prospectsmentioning

confidence: 99%

“…On the other hand, transducers, which convert a biomolecular interaction into a digital signal, are commonly made up of functionalized electrode surfaces. 26,27 Depending on its transducer signal, a biosensor can be electrochemical, optical, thermal, or mechanical. A brief description of each type is as follows: In an electrochemical biosensor, the working electrode functions as the transducer.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Towards Modern-Age Advanced Sensors for the Management of Neurodegenerative Disorders: Current Status, Challenges and Prospects

Gautam

2022

ECS Sens. Plus

View full text Add to dashboard Cite

Neurodegenerative diseases (NDD) are progressive degenerative disorders of the neurological system with significant social impact worldwide. Their detection at the initial stage is necessary to provide proper therapeutic interventions. Biosensors have emerged as one of the next-generation tools for detecting and monitoring physiochemical changes associated with neurological disorders. This article discusses the current status and challenges of different state-of-the-art sensors which can detect NDD biomarkers. A brief overview of developing advanced biosensors with the help of nanotechnology integration, mainly polymer-based functional nanomaterials, has been mentioned as the prospect of these biosensors for NDD detection and management.

show abstract

Section: Prospectsmentioning

confidence: 99%

mentioning

confidence: 99%

Towards Modern-Age Advanced Sensors for the Management of Neurodegenerative Disorders: Current Status, Challenges and Prospects

Gautam

2022

ECS Sens. Plus

View full text Add to dashboard Cite

show abstract

“…Neurodegenerative diseases include a variety of diseases with different pathological patterns and aspects, such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [26]. Given the late onset of ND symptoms, early diagnosis and prompt treatment of ND are paramount [27]. AD is the most common age-related neurodegenerative disorder, causing progressive cognitive decline and irreversible memory impairment.…”

Section: Neurodegenerative Diseasementioning

confidence: 99%

Technological advances in electrochemical biosensors for the detection of disease biomarkers

et al. 2021

View full text Add to dashboard Cite

With an increasing focus on health in contemporary society, interest in the diagnosis, treatment, and prevention of diseases has grown rapidly. Accordingly, the demand for biosensors for the early diagnosis of disease is increasing. However, the measurement range of existing electrochemical sensors is relatively high, which is not suitable for early disease diagnosis, requiring the detection of small amounts of biocomponents. Various attempts have been made to overcome this and amplify the signal, including binding with various labeling molecules, such as DNA, enzymes, nanoparticles, and carbon materials. Efforts are also being made to increase the sensitivity of electrochemical sensors, and the combination of nanomaterials, materials, and biotechnology offers the potential to increase sensitivity in a variety of ways. Recent studies suggest that electrochemical sensors can be a powerful tool in providing comprehensive insights into the targeting and detection of disease-associated biomarkers. Significant advances in nanomaterial and biomolecule approaches for improved sensitivity have resulted in the development of electrochemical biosensors capable of detecting multiple biomarkers in real time in clinically relevant samples. In this review, we have discussed the recent studies on electrochemical sensors for detection of diseases such as diabetes, degenerative diseases, and cancer. Further, we have highlighted new technologies to improve sensitivity using various materials, including DNA, enzymes, nanoparticles, and carbon materials.

show abstract

“…Ideal biomarkers should exhibit high specificity and sensitivity to discriminate survival benefit during the progress and prognosis of disease course. To date, numerous studies have identified a few biomarkers to distinguish ALS from healthy individuals, frontal temporal dementia, and other neurodegenerative diseases (Thompson et al, 2018;Calvo et al, 2019;Yamada et al, 2021); furthermore, biomarkers developed by some of these studies, are of complexity and difficulty in access of tissue, and measurement (Agosta et al, 2018;Thompson et al, 2018;Agnello et al, 2021;Song et al, 2021). As a result of these studies, and given the fact that Abbreviations: ALS, amyotrophic lateral sclerosis; IRGPI, immunerelated gene prognostic index; OS, overall survival; GEO, gene expression omnibus; IRGs, immune-related genes; IL-2, interleukin-2; K-M, Kaplan-Meier; IRPGs, immune-related prognostic genes; LASSO, least absolute shrinkage and selection operator; log2FC, log foldchange; C-index, concordance index; DCA, decision curve analysis; tAUC, timedependent area under the curve; DEGs, differentially expressed genes; CNS, central nervous system; PPI, protein-protein interaction; BBB, blood-brain barrier; PCA, principal components analysis; ALS-FRS, ALS functional rating scale; FVC, forced vital capacity.…”

Section: Introductionmentioning

confidence: 99%

Identification of an immune-related gene prognostic index for predicting prognosis, immunotherapeutic efficacy, and candidate drugs in amyotrophic lateral sclerosis

Wei

Zhu

et al. 2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Rationale and objectivesConsidering the great insufficiency in the survival prediction and therapy of amyotrophic lateral sclerosis (ALS), it is fundamental to determine an accurate survival prediction for both the clinical practices and the design of treatment trials. Therefore, there is a need for more accurate biomarkers that can be used to identify the subtype of ALS which carries a high risk of progression to guide further treatment.MethodsThe transcriptome profiles and clinical parameters of a total of 561 ALS patients in this study were analyzed retrospectively by analysis of four public microarray datasets. Based on the results from a series of analyses using bioinformatics and machine learning, immune signatures are able to be used to predict overall survival (OS) and immunotherapeutic response in ALS patients. Apart from other comprehensive analyses, the decision tree and the nomogram, based on the immune signatures, were applied to guide individual risk stratification. In addition, molecular docking methodology was employed to screen potential small molecular to which the immune signatures might response.ResultsImmune was determined as a major risk factor contributing to OS among various biomarkers of ALS patients. As compared with traditional clinical features, the immune-related gene prognostic index (IRGPI) had a significantly higher capacity for survival prediction. The determination of risk stratification and assessment was optimized by integrating the decision tree and the nomogram. Moreover, the IRGPI may be used to guide preventative immunotherapy for patients at high risks for mortality. The administration of 2MIU IL2 injection in the short-term was likely to be beneficial for the prolongment of survival time, whose dosage should be reduced to 1MIU if the long-term therapy was required. Besides, a useful clinical application for the IRGPI was to screen potential compounds by the structure-based molecular docking methodology.ConclusionUltimately, the immune-derived signatures in ALS patients were favorable biomarkers for the prediction of survival probabilities and immunotherapeutic responses, and the promotion of drug development.

show abstract

Recent advances in enzymeless-based electrochemical sensors to diagnose neurodegenerative diseases

Abstract: This review summarizes the research works of non-enzymatic electrochemical sensors for the early diagnosis of Neurodegenerative disease.

Cited by 29 publications

References 106 publications

Towards Modern-Age Advanced Sensors for the Management of Neurodegenerative Disorders: Current Status, Challenges and Prospects

Towards Modern-Age Advanced Sensors for the Management of Neurodegenerative Disorders: Current Status, Challenges and Prospects

Technological advances in electrochemical biosensors for the detection of disease biomarkers

Identification of an immune-related gene prognostic index for predicting prognosis, immunotherapeutic efficacy, and candidate drugs in amyotrophic lateral sclerosis

Contact Info

Product

Resources

About